The global dental infection market is currently valued at $13.6bn, with a compound annual growth rate (CAGR) of 8.6% (31).
Origin’s initial entry into the dental market is the target indication of Periodontitis. The global Periodontitis market was valued at $0.5bn in 2017, and is projected to grow to $1B by 2026 (a CAGR of 9%) (32).
Periodontitis is one of the most prevalent diseases across the globe, affecting 962 million people above the age of 60 years and is expected to rise two-fold by 2050. The overall burden of periodontal diseases worldwide has increased by nearly 57.3% from 1990 to 2010. Periodontitis is a major cause of tooth loss among the adult population but its full impact results in additional health care and socio-economic costs. In addition to directly affecting nutrition, self-esteem, and quality of life, sufferers are also at major risk of acquiring edentulism and masticatory dysfunction (42).
As a potent anti-microbial (4-8), NO is a promising agent for the treatment of intra-oral infections. In a planned collaboration with a leading academic dental research university, periodontitis will be Origin’s first entry of IonoJet™ technology for dental applications.